Outcome | Exposure | Method | nsnp | P-value | OR | 95%CI | PFDR |
---|---|---|---|---|---|---|---|
OC | 4-acetamidobutanoate | IVW | 43 | 0.026 | 1.78 | 1.07-2.95 | 0.772322416 |
WM | 43 | 0.024 | 2.13 | 1.10-4.11 | Â | ||
MR Egger | 43 | 0.008 | 6.45 | 1.76-23.72 | Â | ||
OC | alpha-hydroxyisovalerate | IVW | 17 | 0.016 | 1.49 | 1.08-2.05 | 0.65956674 |
WM | 17 | 0.035 | 1.60 | 1.03-2.48 | Â | ||
MR Egger | 17 | 0.254 | 1.76 | 0.69-4.46 | Â | ||
OC | asparagine | IVW | 46 | 0.024 | 0.65 | 0.45-0.95 | 0.772322416 |
WM | 46 | 0.004 | 0.44 | 0.25-0.77 | Â | ||
MR Egger | 46 | 0.028 | 0.42 | 0.19-0.89 | Â | ||
OC | 3-(3-hydroxyphenyl) propionate | IVW | 11 | 0.018 | 1.17 | 1.03-1.32 | 0.65956674 |
WM | 11 | 0.040 | 1.20 | 1.01-1.44 | Â | ||
MR Egger | 11 | 0.428 | 1.16 | 0.82-1.63 | Â | ||
OC | X-13183--stearamide | IVW | 11 | 0.008 | 1.40 | 1.09-1.80 | 0.65956674 |
WM | 11 | 0.025 | 1.49 | 1.05-2.12 | Â | ||
MR Egger | 11 | 0.158 | 1.49 | 0.90-2.48 | Â | ||
MOC | 1,5-anhydroglucitol (1,5-AG) | IVW | 31 | 0.016 | 2.33 | 1.17-4.64 | 0.851594997 |
WM | 31 | 0.023 | 3.21 | 1.18-8.77 | Â | ||
MR Egger | 31 | 0.052 | 5.77 | 1.06-31.43 | Â | ||
MOC | ADpSGEGDFXAEGGGVR | IVW | 7 | 0.005 | 2.52 | 1.33-4.77 | 0.851594997 |
WM | 7 | 0.003 | 3.48 | 1.54-7.89 | Â | ||
MR Egger | 7 | 0.232 | 3.93 | 0.55-28.20 | Â | ||
OCCC | betaine | IVW | 24 | 0.033 | 0.21 | 0.05-0.88 | 0.981998335 |
WM | 24 | 0.013 | 0.10 | 0.02-0.61 | Â | ||
MR Egger | 24 | 0.105 | 0.05 | 0.00-1.59 | Â | ||
OCCC | estrone 3-sulfate | IVW | 13 | 0.049 | 1.32 | 1.00-1.75 | 0.981998335 |
WM | 13 | 0.014 | 1.59 | 1.10-2.29 | Â | ||
MR Egger | 13 | 0.408 | 1.21 | 0.78-1.88 | Â | ||
OCED | 3-(3-hydroxyphenyl) propionate | IVW | 11 | 0.003 | 1.52 | 1.16-2.00 | 0.693730355 |
WM | 11 | 0.005 | 1.70 | 1.17-2.46 | Â | ||
MR Egger | 11 | 0.045 | 2.34 | 1.14-4.77 | Â | ||
OCED | 1,5-anhydroglucitol (1,5-AG) | IVW | 31 | 0.011 | 2.35 | 1.22-4.53 | 0.693730355 |
WM | 31 | 0.030 | 2.65 | 1.10-6.40 | Â | ||
MR Egger | 31 | 0.406 | 2.00 | 0.40-10.07 | Â | ||
OCED | arachidonate (20:4n6) | IVW | 20 | 0.033 | 0.38 | 0.16-0.92 | 0.748839011 |
WM | 20 | 0.007 | 0.20 | 0.06-0.64 | Â | ||
MR Egger | 20 | 0.031 | 0.17 | 0.04-0.75 | Â | ||
OCED | 1-linoleoylglycerophosphoethanolamine | IVW | 11 | 0.014 | 2.98 | 1.24-7.13 | 0.693730355 |
WM | 11 | 0.025 | 4.18 | 1.19-14.66 | Â | ||
MR Egger | 11 | 0.181 | 5.56 | 0.55-56.35 | Â | ||
OCED | stearidonate (18:4n3) | IVW | 11 | 0.023 | 0.36 | 0.15-0.87 | 0.694101869 |
WM | 11 | 0.039 | 0.30 | 0.09-0.94 | Â | ||
MR Egger | 11 | 0.098 | 0.10 | 0.01-1.15 | Â | ||
OCED | ADpSGEGDFXAEGGGVR | IVW | 7 | 0.040 | 2.35 | 1.04-5.29 | 0.748839011 |
WM | 7 | 0.009 | 2.94 | 1.30-6.62 | Â | ||
MR Egger | 7 | 0.023 | 19.77 | 3.22-121.42 | Â | ||
SOC | X-13183--stearamide | IVW | 11 | 0.008 | 1.48 | 1.11-1.97 | 0.871510468 |
WM | 11 | 0.026 | 1.58 | 1.06-2.37 | Â | ||
MR Egger | 11 | 0.150 | 1.61 | 0.89-2.90 | Â | ||
SOC | DSGEGDFXAEGGGVR | IVW | 13 | 0.023 | 0.73 | 0.56-0.96 | 0.952113534 |
WM | 13 | 0.024 | 0.65 | 0.44-0.94 | Â | ||
MR Egger | 13 | 0.092 | 0.47 | 0.21-1.05 | Â | ||
SOC | 2-hydroxyhippurate (salicylurate) | IVW | 13 | 0.028 | 0.93 | 0.87-0.99 | 0.952113534 |
WM | 13 | 0.035 | 0.90 | 0.82-0.99 | Â | ||
MR Egger | 13 | 0.184 | 0.91 | 0.80-1.04 | Â |